ARQL News and Press, ArQule Inc. From 12/09/19

NEW YORK, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of ArQule, Inc. (NASDAQ: ARQL) to Merck for $20.00 per share is fair to ArQule shareholders. On behalf of ArQule shareholders, Halper Sadeh LLP may seek increas...

DENVER, Colo., December 9, 2019- (24/7MarketNews via COMTEX) Venture Market News for December 9, 2019. Market Trend As the US-China trade talks may continue to try to take up all the air in the room, biotech M&A activity is quietly picking up, with two high premium acquisitions in the spce...

Synthorx (NASDAQ: THOR ) +169%  on being acquired by Sanofi. More news on: Synthorx, Inc., XBiotech Inc., ArQule, Inc., Stocks on the move, Read more ...

- ARQ 531 demonstrates substantial anti-tumor activity and manageable safety profile - Eight of nine evaluable CLL patients initially dosed at ≥65 mg experienced a Partial Response (PR) - Five of five CLL patients that were evaluable at the third scan (cycle 9) are durable ...

Merck (NYSE: MRK ) has agreed to acquire ArQule (NASDAQ: ARQL ) for $20 per share in cash, valuing the transaction at $2.7B. More news on: Merck & Co., Inc., ArQule, Inc., Healthcare stocks news, Stocks on the move, Merger & acquisition news, Read more ...

Acquisition Further Diversifies Merck’s Oncology Pipeline with Expansion into Targeted Therapies That Treat Hematological Malignancies Merck (NYSE: MRK), known as MSD outside the United States and Canada, and ArQule, Inc. (Nasdaq: ARQL) today announced that the companies have e...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks ...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

It's nearly time for the annual get-together of the American Society of Hematology (ASH). There will be presentations from too many drugmakers for any one person to absorb, but at least three will be worthy of more attention than most. A cellular cancer therapy from Celgene that Bristol-Myers ...

This has been a banner year for three biotech stocks and their shareholders. All of them have soared in response to promising clinical trial results for some very different experimental therapies. If you're not sure why these stocks are among the biotech industry's top performers, let's review ...